GenScript Biotech Corporation
GenScript Biotech Corporation (Stock Code: 1548.HK) is the world’s leading technology and service provider of life science R&D and manufacture. Built upon its solid gene synthesis technology, GenScript Biotech is divided into four major platforms including the life science service and product platform, the biologics contract development and manufacturing organization (CDMO) platform, the global cell therapy platform and the industrial synthesis biological product platform.
GenScript Biotech was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript Biotech's business operations span over 100 countries and regions worldwide with legal entities located in the US, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands and Ireland. GenScript Biotech provides premium, convenient and reliable services and products for over 100,000 customers.
As of June 30, 2021, GenScript Biotech had more than 4500 employees globally, over 40% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript Biotech owns a number of intellectual property rights, including over 160 patents, over 600 pending patent applications and great numbers of trade secrets.
Driven by the corporate mission of “making people and nature healthier through biotechnology”, GenScript Biotech strives to become the most trustworthy biotech company in the world. As of June 30, 2021, GenScript Biotech's services and products have been cited by 64,700 peer-reviewed journal articles worldwide.
For more information, please visit GenScript Biotech's official website
https://www.genscript.com.